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ABSTRACT 96 
Background. Night shift work, exposure to light-at-night and the consequent circadian 97 
disruption may increase the risk of hormone-dependent cancers. 98 
Objectives. We evaluated the association of exposure to artificial light at night (ALAN) 99 
during sleeping time with breast and prostate cancer in a population based multicase-100 
control study (MCC-Spain), among subjects who had never worked at night. We took 101 
into account chronotype, a characteristic that may relate to adaptation to light-at-night.  102 
Methods. We enrolled 1219 breast cancer cases, 1385 female controls, 623 prostate 103 
cancer cases and 879 male controls from 11 Spanish regions, 2008-2013. Indoor-ALAN 104 
information was obtained through questionnaires and outdoor-ALAN was analyzed 105 
using images from the International Space Station (ISS) available for Barcelona and 106 
Madrid, including data of remotely sensed upward light intensity and blue light 107 
spectrum information for each geocoded longest residence of each MCC-Spain subject. 108 
Results. Among participants with information on both indoor and outdoor ALAN, 109 
exposure to higher levels of blue light spectrum (outdoor-ALAN) was associated with 110 
an increased risk of breast (adjusted odds ratio OR=1.54, 95%CI 1.0-2.4) and prostate 111 
cancer (OR=1.90, 95%CI 1.2-2.9). Overall light intensity (outdoor-ALAN) was not 112 
associated with cancer risk. Those sleeping in more illuminated bedrooms (indoor-113 
ALAN) had a higher risk of prostate cancer [OR=2.82, 95%CI 1.5-5.3] while there was 114 
no clear association for breast cancer (OR=1.19, 95%CI 0.6-2.6). Evening types tended 115 
to have slightly higher prostate cancer risks.    116 
Conclusion. Both indoor and outdoor ALAN and particularly blue enriched light 117 
spectrum were associated with an increased risk of breast and prostate cancer. 118 
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INTRODUCTION 119 
The increase of artificial light at night (ALAN) in cities has altered the natural light 120 
levels in the nocturnal environment and extended human activities into the usually dark 121 
hours (Falchi et al. 2011). It has been estimated that more than 80% of the world 122 
population (99% of the population from USA and Europe) and almost one-fifth of the 123 
world terrain is under light polluted skies (Cinzano et al. 2001, Falchi et al. 2011, Falchi 124 
et al. 2016).  125 
Depending on light intensity and wavelength, exposure to ALAN may affect human 126 
health by decreasing the production and secretion of pineal melatonin (N-acetyl-5-127 
methoxytriptamine), which is a hormone normally produced in the dark phase of the 128 
24h cycle (Brainard et al. 2001; Chang et al. 2014; Escofet and Bará 2015; Thapan et al. 129 
2013). Melatonin may be involved in epigenetic regulation of limiting cancer initiation 130 
and progression by reducing severe DNA damage that is a consequence of unstable 131 
oxygen and nitrogen-based reactants (Korkmaz and Reiter 2011).  132 
Those mechanisms led the International Agency for Research on Cancer (IARC) to 133 
conclude that shift work which involves circadian disruption is “probably carcinogenic 134 
to humans” (IARC, 2007). Differences between day and night shift workers and 135 
circadian variation of melatonin production and light exposure have been evaluated 136 
showing the lower melatonin levels in night workers.  137 
Moreover, the genetic background of each individual can affect the ability to have a 138 
preferential day or night profile (chronotype), the adaptation to night work and changes 139 
in sleep and wake schedules, and can define groups more or less susceptible to effects of 140 
circadian cycle disruption. For instance, Papantoniou et al (2014) identified the lowest 141 
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melatonin levels among night shift workers with morning preference chronotype, an 142 
individual characteristic that may relate to night shift work adaptation.  143 
Furthermore, genetic (and epigenetic) mechanisms of cycle regulation are well 144 
described and include negative auto regulated transcription models of genes (Chellappa 145 
et al. 2011). For instance, melatonin suppresses both estrogen receptor positive (ERα) 146 
mRNA expression and estrogen induced transcriptional activity of the ERα in (ERα+) 147 
human breast cancer cells (Hill et al. 2015). 148 
Nevertheless, the IARC evaluation examined occupational rather than environmental 149 
exposures and only few studies, most of them based on ecological comparisons, have 150 
measured the direct impact of ALAN in cities on circadian rhythms and hormone-151 
dependent cancers. Nighttime satellite photometry, collected in the framework of the 152 
U.S. Air Force Defense Meteorological Satellite Program—Operational Linescan 153 
System (DMSP-OLS), has been used for mapping sky brightness and built surfaces 154 
(Cinzano et al. 2000). Even though data obtained from satellite images are only able to 155 
detect the intensity of light but not to measure the spectrum of nighttime lighting 156 
emissions, different studies used this source of information to link the ALAN intensities 157 
captured by DMSP-OLS with incidence rates of breast and prostate cancer and found a 158 
significant positive association (Kloog et al. 2009, 2010).  Furthermore, Rybnikova et 159 
al. (2015, 2016), reanalyzed Kloog and co-authors work, using GLOBOCAN, US-160 
DMSP and World Bank’s 2002 and 2012 databases, controlling for several country-161 
level predictors, including birth rates, percent of urban population, per capita GDP and 162 
electricity consumption. They found a significant positive breast and prostate cancer-163 
ALAN association once the data were reorganized in geographic clusters of similarly 164 
developed countries. Additionally, further studies (Bauer et al. 2013; Hurley et al., 165 
2014; Keshet-Shitton et al. 2015; Kloog et al. 2011) combined Indoor ALAN estimates, 166 
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based on questionnaire data regarding sleep habits and use of night time lighting, with 167 
estimates of outdoor ALAN obtained from DMSP-OLS or also from questionnaires, to 168 
evaluate the association with breast cancer, concluding that decreasing nighttime light 169 
exposure diminished breast cancer risk. All studies cited above used DMSP-OLS 170 
satellite data that are blind to the blue content of ALAN because of a lack of sensor 171 
sensitivity in that part of the visible spectrum. 172 
We have recently shown in a population based case-control study in Spain (MCC-173 
Spain) an overall higher risk of breast and prostate cancer among night shift workers 174 
(Papantoniou et al. 2015a, Papantoniou et al. 2015b). In the present analysis, we 175 
evaluated in the same study among non-night shift workers, the association of breast 176 
cancer and prostate cancer risk with the level of reported indoor ALAN during sleeping 177 
time and with remotely sensed levels of outdoor ALAN light intensity and colour 178 
(spectral content), individually assigned to geocoded addresses of study participants. 179 
MATERIALS AND METHODS 180 
Study population 181 
The MCC-Spain is a population based multicase-control study (www.mccspain.org) on 182 
frequent tumours in Spain that includes 23 hospitals in 12 regions and assesses 5 types 183 
of cancer (breast, colorectal, prostate and stomach cancers and chronic lymphocytic 184 
leukaemia) using the same series of population controls for all cases (Castaño-Vinyals 185 
et al. 2015). In this analysis we focus only on breast and prostate cancer which are 186 
hormone-regulated type of cancers previously reported to be linked with ALAN 187 
exposures in the literature.  188 
Recruitment of incident cancer cases and population controls aged 20-85 took place 189 
from 2008 to 2013. We recruited cases with an incident histologically confirmed 190 
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diagnosis of cancer, living in the catchment area of each selected hospital for at least 6 191 
months. Controls were randomly selected from the Primary Health Centres (PHC) 192 
located in the same catchment area as cases with no history of cancer and were 193 
frequency matched to cases by sex, age in 5-year age groups and study area. They were 194 
contacted on behalf of their General Practitioner and invited to participate in the study. 195 
Excluded subjects included those incapable of participating in the interview due to 196 
communication difficulties (i.e. mental or speaking problems) and/or excess impairment 197 
of physical ability. Response rates varied by centre with an average 72% response rate 198 
among cases and a 52% among controls with valid telephone numbers in the PHC 199 
rosters. 200 
Data collection 201 
Data was collected through face-to-face interviews performed by trained personnel 202 
including lifetime residential and occupational history. Information on other risk factors 203 
for breast or prostate cancer was collected such as age, educational level, family 204 
socioeconomic level, race, body mass index (BMI), family history of cancer, smoking 205 
status, and in women age of menarche, parity, age at the first birth, menopausal status, 206 
oral contraceptive use and history of hormonal replacement therapy. Leisure time 207 
physical activity information (type, frequency and duration) was available for all 208 
activities held over lifetime. Current sleep duration and sleep problems (waking up 209 
during the night, problems falling asleep, use of sleep medication) that persisted for at 210 
least 1 year were also assessed. Diet habits as well as current and past (at 30-40 years of 211 
age) alcohol consumption was reported for all cases and controls through a self-212 
administered diet questionnaire. Individual chronotype was assessed through a follow-213 
up phone interview and the use of the Munich Chronotype Questionnaire (MCTQ). 214 
Chronotype (MSFcorr) was estimated as the mid-sleep time on free days [MSF=(sleep 215 
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onset on free day+sleep duration on free day)/2)], corrected for oversleep on free days 216 
compared to working days [MSFcorr=MSF – (sleep duration on free day-sleep duration 217 
on a working day)/2]. Chronotype was assessed using categorical variables with 3 218 
categories: morning type (corresponding to MSF<04:00 hr); intermediate/neither type 219 
(MSF=04:01–05:00 h; and evening type MSF>05:00 hr (Papantoniou et al. 2015abc).  220 
 221 
The MCC-Spain study followed the national and international directives namely the 222 
deontological code and declaration of Helsinki and the Spanish law on confidentiality of 223 
data (Ley Organica 15/1999 de 13 Diciembre de Proteccion de Datos de carácter 224 
personal -LOPD). All subjects that agreed to participate and fulfilled the eligibility 225 
criteria signed an informed consent form before participating in the study. The 226 
corresponding ethics committees of the participating centres and hospitals reviewed the 227 
protocol of the study.  228 
Tumour subphenotypes 229 
Breast cancer cases were subclassified into 3 subtypes based on local pathology reports: 230 
(1) ER/PR+ tumours with luminal human epidermal growth factor receptor 2 negative 231 
(HER2-)  and oestrogen receptor positive (ER+) or progesterone receptor positive 232 
(PR+); (2) HER2+ tumours with luminal human epidermal growth factor receptor 2 233 
positive (HER2+) irrespective of oestrogen or progesterone receptor results;  (3) TN 234 
(triple-negative) tumours with ER-, PR- and HER2-.  235 
Prostate cancer cases were evaluated by degree of differentiation/grade using the 236 
prostate biopsy Gleason score (7 or lower: well or moderately differentiated; 8 or above 237 
poorly differentiated- more aggressive).  238 
 239 
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Artificial light-at-night (ALAN) exposures 240 
To evaluate the effect of indoor-ALAN exposure, study cases and controls from breast 241 
and prostate cancer were selected from 11 MCC-Spain participating areas (Asturias, 242 
Barcelona, Cantabria, Girona, Granada, Guipúzcoa, Huelva, León, Madrid, Navarra and 243 
Valencia). In order to analyze the effect of ALAN during sleeping time, we excluded 244 
subjects who had ever worked in night-shift   (i.e. working schedule that involved 245 
working partly or entirely between 00:00 and 06:00h, at least three times per month). 246 
Due to this condition we excluded 224 breast cases, 208 female controls, 327 prostate 247 
cases and 353 male controls.  248 
We evaluated indoor-ALAN through the MCC-Spain questionnaire where it was 249 
defined as the level of light in the bedroom during sleeping time when the participants 250 
were at 40 years of age. This was a subjective measure requested during the face-to-face 251 
interview using a four digit Likert scale. The scale used four values: (1) Total darkness; 252 
(2) Almost dark; (3) Dim light; and (4) Quite illuminated. 253 
For the evaluation of outdoor-ALAN we used images of Madrid (Figure 1) and 254 
Barcelona (Figure 2), taken by astronauts aboard the ISS in 2012 (ISS030-E-82053) and 255 
2013 (ISS045-E-120336), respectively. The images were downloaded from the Earth 256 
Science and Remote Sensing Unit, NASA Johnson Space Centre (url: 257 
https://eol.jsc.nasa.gov). Those images were taken with commercial Digital Single-Lens 258 
Reflex (DSLR) cameras providing image information in three spectral bands, in the 259 
visual range (red (R), green (G), blue (B); i.e. RGB) and with the European Space 260 
Agency NightPod system (installed in 2012). These instruments may provide ground 261 
level resolutions of less than 10 meters (Kyba et al. 2016) but in the images included in 262 
the present analysis the spatial resolution was about 30 meters. The images were 263 
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calibrated applying the procedure described in Sánchez de Miguel (2015), by using 264 
existing databases of standard typical emission spectra of known types of outdoor 265 
lighting (white LED, low pressure sodium, metal halide, etc) and inferring the observed 266 
lighting type from the RGB signature (Sánchez de Miguel et al. 2007; Sánchez de 267 
Miguel 2014). More specifically, we used the G/R ratio, to proceed to the classification 268 
of the ground level spectral type of the lamps and then we used a lamp spectral database 269 
to estimate the ground based spectrum of the light emissions (Figure 3).  In the 270 
estimation we assume the atmospheric transfer function and the ground reflectance to 271 
not affect much the classification process.  272 
An estimate of the visual light was done using a relationship between the ratio of the 273 
photopic visual light over the green band fluxes detected from the ISS (V(λ)/G) to the 274 
ratio of the green to the red bands (G/R). This relationship has been determined for a 275 
variety of lighting technologies by Sánchez de Miguel (2015) (Figure 4).  276 
We also calculated an index of outdoor blue light spectrum using an approach described 277 
in Aubé et al. (2013) to calculate the melatonin suppression index (MSI) at each pixel of 278 
the image. The MSI is related to exposure to blue light and is a metric designed to scale 279 
the spectral interaction between a given light spectrum and the published measurements 280 
of the melatonin suppression action spectrum (MSAS) (Brainard et al. 2001; Thapan et 281 
al. 2001). The MSI has been designed to separate the effect of the shape of a spectrum 282 
from its averaged luminous intensity by making use of the MSAS. The MSI 283 
determinations were done for the house location of each participant involved in the 284 
study and derived as a number generally ranging from 0 to 1. The MSI represents to 285 
what extent the spectrum shape of different lights are efficient to suppress the melatonin 286 
production compared to the spectrum shape of the CIE’s illuminant D65 that has been 287 
arbitrarily set to the highest value (one). The International Commission on Illumination 288 
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(CIE) Standard Illuminant D65 corresponds approximately to the average midday 289 
sunlight in Western and Northern Europe. 290 
Therefore, two quantitative indices of outdoor-ALAN were estimated from space based 291 
colour imagery: (1) outdoor visual-ALAN, as a proxy for luminance and (2) Melatonin 292 
Suppression Index (MSI), which is highly linked to blue light spectrum and MSAS.  293 
A geographic information system (GIS), QGIS (QGIS Development Team, 2015) was 294 
used to assign outdoor-ALAN levels of visual light (outdoor visual-ALAN) and MSI to 295 
each individual cases and controls locations from MCC-Spain study, selecting the 296 
geocoded residence with the longest duration for each participant. 297 
Statistical analysis 298 
We used generalized additive models (GAMs) to examine the shape of the dose-299 
response relationship between indoor/outdoor ALAN exposure and risk of cancer. We 300 
applied unconditional logistic regression and calculated adjusted ORs and 95% CIs in 301 
separate and combined models of indoor and/or outdoor ALAN exposures for each of 302 
the two cancers. In order to be able to include both indoor and outdoor ALAN 303 
information in the same model, we selected those participants from Barcelona and 304 
Madrid which were 40 years of age by the time they were living in their longest 305 
residence.  306 
Models were adjusted a priori (basic adjustment) for age, centre (participant cities) and 307 
educational level (less than primary school; primary school; secondary school and 308 
university); breast cancer models included also adjustment for menopausal status. A 309 
further adjustment was also carried out including the previous variables and also: body 310 
mass index (BMI) treated as a categorical variable: normal weight (0 to <25), 311 
overweight (25 to 30) and obese (≥30);  urban vulnerability to measure socioeconomic 312 
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status at area level coded from 0 to 1; family history of breast/prostate cancer;  alcohol 313 
intake at age 40 (gr/day); smoking habits (ever smoked at least 100 cigarettes or 360 gr 314 
of tobacco vs. none) and chronotype information (morning, evening vs. intermediate).  315 
We analyzed effects on subphenotypes of the diseases using multinomial logistic 316 
regression applying the basic adjustment for breast and prostate cancer. Chronotype was 317 
also examined in a stratified analysis. 318 
All statistical analyses were performed using DeduceR package (Fellows, 2012) within 319 
R software environment (R core team, 2016). 320 
RESULTS 321 
Study population 322 
A total of 1219 cases and 1385 controls for breast cancer and 623 cases and 879 323 
controls for prostate cancer were the initially selected population from MCC-Spain 324 
study, including information of indoor ALAN exposures, after excluding participants 325 
who had worked as night shift workers. The distribution of potential breast and prostate 326 
cancer risk factors among selected participants for indoor-ALAN model are shown in 327 
Table 1 and 2, respectively. 328 
From the initially selected population, around 30% of female population and 50% of 329 
male population had a BMI of 25-30. Female cases were slightly younger than controls 330 
(55.8; SD 11.8 vs 58.8; SD 12.6 years), less often postmenopausal (63.8 vs 71.7 %), 331 
reported more frequently family history of breast cancer (14.8 vs 9.3 %) compared to 332 
controls, and consumed more alcohol (6.2 vs 5.2 gr/day). Male cases also reported more 333 
frequently family history of prostate cancer than controls (16.5 vs 6.5%) and consumed 334 
a higher amount of alcohol compared to controls (31.9 vs 28.7 gr/day). A total of 2578 335 
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females and 1475 males completed the chronotype questionnaire. Additionally, clinical 336 
information from medical records analyzed for 412 breast cancer cases, including 337 
tumour hormonal receptor status, and for 433 prostate cases with information of 338 
Gleason score. 339 
For the outdoor-ALAN model, we selected a total of 446 cases and 568 controls of 340 
breast cancer and 438 cases and 660 controls for prostate cancer, living in Madrid and 341 
Barcelona from MCC-Spain study. The study characteristics and distribution of risk 342 
factors for the subsample, for which environmental outdoor-ALAN estimates were 343 
available, are also shown in Table 1 and 2. For nearly all variables, distributions are 344 
very similar for the main population and the subsample.  345 
Indoor and outdoor ALAN models 346 
The associations between indoor-ALAN exposure models, evaluated in the whole 347 
Spanish study population, for breast and prostate cancer are shown in Table 3. Results 348 
were very similar for basic and further adjustments. We observed an OR of 2.56 (CI 349 
95%: 1.57, 4.17) for prostate cancer cases exposed to the highest level of indoor 350 
illumination during bedtime, reported as “quite illuminated” compared to those 351 
reporting sleeping “in total darkness”. No association was found for breast cancer 352 
(OR=0.95, CI 95%: 0.64, 1.42). 353 
We could only evaluate the joint effect of indoor and outdoor ALAN for the population 354 
in Barcelona and Madrid. Outdoor-ALAN variables were included into the models as 355 
categorical variables using tertiles of exposure. Original values were used for the GAM 356 
models. Visual light data (units proportional to the luminance, a quantity generally 357 
expressed in units of Cd/m2) had an average of 0.065 (SD: 0.034; Min: 0.009; Max: 358 
0.225) for breast cancer and an average of 0.066 (SD: 0.034; Min: 0.002; Max: 0.225) 359 
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for prostate cancer.  Values of MSI had an average of 0.152 (SD: 0.046; Min: 0.041; 360 
Max: 0.407) for breast cancer and an average of 0.151 (SD: 0.047; Min: 0.017; Max: 361 
0.412) for prostate cancer. No correlation was found between indoor-ALAN and 362 
outdoor-ALAN either for MSI or visual, in the subsample population of Barcelona and 363 
Madrid. 364 
In GAM models (Figure 5), we observed a non-linear relationship in prostate cancer 365 
both for visual light (outdoor ALAN) and for MSI- blue light (outdoor ALAN) with p-366 
values for departure from linearity of p=0.031 and p=0.062 respectively. There was no 367 
significant departure from linearity for breast cancer. All subsequent analyses are based 368 
on tertiles of exposure.   369 
 In further adjustment models (Table 4)., also mutually adjusted for outdoor and indoor 370 
ALAN, we found that those sleeping in more illuminated bedrooms (indoor-ALAN) had 371 
a higher risk of prostate cancer [OR=2.82, 95%CI 1.5-5.3] while there was only a slight 372 
increased risk for breast cancer (OR=1.19, 95%CI 0.6-2.6). Exposure to higher levels of 373 
blue light spectrum (outdoor-ALAN; highest tertile of MSI) was associated with an 374 
increased risk of both breast (adjusted odds ratio OR=1.54, 95%CI 1.0-2.4) and prostate 375 
cancer (OR=1.90, 95%CI 1.2-2.9) cancers.  Overall visual light (outdoor-ALAN) was 376 
not associated with cancer risk. 377 
Chronotype and tumour subphenotypes 378 
For stratified analyses by chronotype and tumour subphenotypes we present results for 379 
the basic adjustment models so as to have a larger population sample size. However risk 380 
estimates were of similar direction for fully adjusted models.   381 
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Exposure to higher levels of blue light spectrum (outdoor-ALAN; highest tertile of 382 
MSI) was associated with slightly higher  risks for estrogen or progestagen positive 383 
receptor breast cancer tumours (OR=1.27, 0.87, 1.85) but differences with Her+ positive 384 
and triple negative tumours were not marked (Table 5). For prostate cancer exposure to 385 
blue light (outdoor-ALAN; highest tertile of MSI) indicated similar risks in more 386 
aggressive cancers with a Gleason scores of 7 or higher (OR=1.70; CI 95%: 1.05, 2.53) 387 
and in less aggressive tumour with Gleason below 7 (OR=1.57, 1.05- 2.34) (Table 5).  388 
The highest prostate cancer risk for exposure to indoor-ALAN during sleep time was 389 
observed in participants with evening chronotype (OR=6.2; CI 95%: 2.01, 19.21) 390 
(Supplemental Material, Table S1); risk for morning types was also elevated but lower 391 
(OR=1.74, 1.0-3.2). No differences were observed by chronotype and indoor ALAN for 392 
breast cancer (Supplemental, Table S1). There were no marked differences by morning, 393 
intermediate or evening chronotypes in relation to risk associated with levels of blue 394 
light spectrum (outdoor-ALAN; MSI), neither for prostate nor for breast cancer 395 
(Supplemental Material, Table S2). However, for prostate cancer ORs tended to be 396 
higher in evening compared to morning or intermediate chronotypes.  397 
DISCUSSION 398 
We evaluated the association between exposure to indoors and outdoors artificial light-399 
at-night (ALAN) during sleep time and breast and prostate cancer risk, two cancers that 400 
have been associated with circadian disruption. We found that outdoor light at night and 401 
specifically exposure to blue light that has been shown to reduce melatonin levels was 402 
associated with an increased risk of both prostate and breast cancer. Indoor-ALAN was 403 
associated with an increased risk of prostate cancer. Evening types tended to have 404 
slightly higher risk but overall we did not find a clear pattern of risk with chronotype. 405 
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Even though we applied in this study more accurate methods for the evaluation of light 406 
exposure compared to previous studies, exposure assessment remains a key issue when 407 
examining the potential health effects of artificial light-at-night in human studies.  408 
Exposure to ALAN is ubiquitous and a public health issue is whether the spread of 409 
exposure to ALAN may increase cancer risk and how could this be prevented. Exposure 410 
to short wavelength light colour during the hours before bedtime has been shown to 411 
suppress nocturnal melatonin production in the pineal gland which, in turn, has been 412 
associated with an increased risk of hormone-dependent type of cancers such as breast 413 
and prostate cancer (Cajochen et al. 2005; Chang et al. 2014; Gringras et al. 2015; 414 
Keshet-Shitton et al. 2015; Papantoniou et al. 2014; Stevens et al. 2015).  415 
Artificial night time lighting is especially widespread and changing rapidly and most 416 
countries across Europe are experiencing marked increases in night time brightness 417 
(Bennie et al. 2014), especially with the massive arrival and exponential growth of 418 
Light Emitting Diodes (LED) in the way of replacing the incandescent and high 419 
pressure sodium lamps (Sanchez de Miguel et al. 2017). Moreover, the increase in 420 
ALAN exposure has been widely recognized to be an ecological problem (Gaston et al. 421 
2015). Even though different measures can be implemented to reduce ALAN exposure 422 
indoors, it is more complex to deal with the inappropriate and unshielded outdoor 423 
lighting (Escofet and Bará 2015).  424 
Existing studies examining ALAN exposures and cancer risk rates have relied almost 425 
exclusively on satellite data, primarily from the Defense Meteorological Satellite 426 
Program/Operational Linescan System (DMSP/OLS; e.g. Cinzano et al. 2001, Bennie et 427 
al. 2014), and more recently the Visible Infrared Imaging Radiometer Suite (VIIRS) 428 
with its Day-Night Band camera onboard the Suomi National Polar-Orbiting 429 
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Partnership (Suomi NPP) satellite (e.g. Baugh et al. 2013). In particular, the satellite 430 
sensors from which the data have been obtained are effectively ‘colour blind’, able to 431 
detect the intensity of light integrated across a range of wavelengths but not to measure 432 
the spectrum of night time lighting emissions. Moreover both satellite platforms are 433 
insensitive to the blue content of the light. As a consequence, very little is known about 434 
the spatial and temporal dynamics of the spectrum of artificial night time lighting 435 
systems (Gaston et al. 2015). This is critical for at least two reasons. First, almost all 436 
known environmental impacts of artificial night time lighting are sensitive to the 437 
spectrum of that lighting including melatonin production (Aubé et al. 2013); second, 438 
these changes in physiological parameters may in turn influence circadian rhythms and 439 
hence timing of sleep, blood pressure regulation, seasonal reproduction and the role of 440 
melatonin as an antioxidant (Korkmaz and Reiter, 2011), with consequences for the 441 
prevalence of some kinds of cancer (e.g. Cajochen et al. 2005). 442 
We applied new methods available that make it feasible to convert International Space 443 
Station (ISS) images with simple three-band spectral information into ecological risk 444 
maps, using known spectral responses of key physiological and ecological processes 445 
with a higher spatial resolution (up to 10 meters), rather than those images obtained 446 
from the VIIRS/DNB platform (750 m) or DMSP/OLS (3.5 km). In common with other 447 
remotely sensed data on artificial light at night, the maps we produced also represent 448 
light emitted or reflected upwards towards the sensor assuming that this is a good proxy 449 
for the intensity and density of light sources at ground level. It would be interesting in 450 
further studies to include information about the aerosol content of the atmosphere in 451 
order to correct the ISS images by differential atmospheric absorption. 452 
The methodology we used provides information on the spatial distribution and on the 453 
temporal evolution of the luminance next to the participant houses, depending on the 454 
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available ISS images. Note that when a change in the spectral technology is made (e.g. 455 
when changing High Pressure Sodium (HPS) lamps for white LEDs), illuminances are 456 
usually maintained constant on the street level.  But in some cases a change in the 457 
lateral photometry of the light fixtures can result in a significant change of the 458 
luminance entering the bedroom windows even if the street illuminance is maintained. 459 
The ISS data cannot identify such an effect and there is inevitably an unquantifiable 460 
error when determining the window level luminance.  461 
Results of the present study showed a higher risk association between exposure to 462 
outdoor- blue-light spectrum (MSI), independently from outdoor visual-ALAN (i.e. 463 
luminance), for prostate and breast cancer. Visual light estimates are based on what the 464 
cameras detect from space while there is a part of the light emitted that might never 465 
enter the houses. Moreover, the luminance at the window level is linked in a complex 466 
way to ground-based light emissions while taking into account atmospheric-induced 467 
optical distortion as well as spectral and geometrical transformations from the 468 
underlying ground surfaces and obstacles (Aubé 2015). In other words, the light output 469 
pattern of the light fixtures cannot be assessed from space and it is possible that the 470 
upward light remains weakly correlated to the horizontal light that enters the houses. 471 
There is less of this problem with MSI. The only variation on the spectrum can come 472 
from different combinations of direct and reflected lights as a function of the angle but 473 
generally the most important contribution to the light entering a window is the direct 474 
light and for that component MSI does not depend on the angle. Visual response that we 475 
and others have used to evaluate the outdoor visual-ALAN is poorly correlated to the 476 
blue light. Assessments that have only used visual response are probably missing the 477 
part of the light (blue) which is likely to be important when evaluating biological 478 
responses related to cancer.   479 
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We did not find clear evidences of a differential effect of chronotype, with only a higher 480 
risk of prostate cancer among evening types, who may be subjects getting too much 481 
light in the wrong hours. Previous studies on night shift workers and breast or prostate 482 
cancer have not shown a consistent pattern of risk by chronotype although overall 483 
prostate cancer risk was also higher among subjects with an evening chronotype 484 
(Papantoniou 2015b). Although chronotype is related to preference for morningness or 485 
eveningness, the direct association with long term cancer risk is still unknown.  486 
We found a higher risk of prostate cancer, and slightly similar trend for breast cancer, 487 
among participants with a more illuminated bedroom at night (indoor-ALAN). There 488 
was no association between outdoor visual-ALAN and indoor-ALAN. This lack of 489 
correlation could be due to the use of shutters at night among subjects with high outdoor 490 
visual ALAN, or perhaps a lack of relationship between the light reaching the ISS and 491 
the light reaching the house’s windows. Similar results were described in a previous 492 
study carried out by Rea et al (2011) concluding that satellite-measured sky brightness 493 
(visual light) was unrelated to personal light exposures. Additionally, most human made 494 
surfaces are less reflective in the blue part of the spectrum and the MSI parameters can 495 
be underestimated even though, the results showed a higher correlation with prostate 496 
cancer. Indoor-ALAN measurements are very important to complement outdoor visual-497 
ALAN impact on hormone-dependent cancers in countries like Spain, where the use of 498 
closed curtains or shutters is extended. In addition, other sources rather than street light 499 
might be contributing to indoor-ALAN exposures like light coming from neighbours, or 500 
the use of portable electronic devices with self-luminous displays and energy-efficient 501 
lighting (LEDs). The use of such devices is increasing and has a significant effect on 502 
decreasing melatonin production if they are used before bedtime (Bonmati-Carrion et al. 503 
2014; Chang et al. 2014).  504 
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In further studies it will be interesting to measure indoor light levels rather than using 505 
only questionnaire-based methodology which is more subjective although may be 506 
capturing a longer time span of exposure. Improvements in modelling exposure such as 507 
the inclusion of the height of the building-residences and of different obstacles in the 508 
street like trees or other buildings which could protect from the received outdoor light, 509 
would have been advantageous but also should be validated with light measurements. 510 
Such approaches could help explain our observations where outdoor visual-ALAN (i.e. 511 
luminance) was associated with no or a negative  effect that is opposite to that observed 512 
for blue light (MSI index), which might still penetrate the curtains or shutters (Aubé et 513 
al. 2013). 514 
Summarizing, in this study we used modelled images provided by the International 515 
Space Station (ISS) to map the spatial variation of artificial night time lighting exposure 516 
including blue light spectrum combined with data from questionnaires on exposure to 517 
indoor light at night, and related this information with the risk of developing the two 518 
most common hormone dependent cancers (breast and prostate). The main strengths of 519 
this study are the use of individual information rather than relying on ecological 520 
comparisons as most other studies and the possibility therefore of developing personal 521 
estimates of exposure and adjusting for potential confounding factors. In addition we 522 
used new methods for the evaluation of blue light spectrum. The main limitation of the 523 
study is exposure misclassification since we used proxy estimates for the evaluation of 524 
both indoor-ALAN and for outdoor visual-ALAN exposure (although not for MSI), 525 
although it is unlikely that this would result to differential misclassification between 526 
cases and controls.   527 
 528 
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CONCLUSIONS 529 
This is the first large study using individual information on the two cancers most 530 
strongly associated with circadian disruption and light-at-night during shift work, and 531 
provides some evidence of the importance of artificial light-at-night (ALAN) for the 532 
development of cancer in the general population. Exposure to both indoor and outdoor 533 
ALAN was associated with a higher risk of prostate cancer while findings were less 534 
consistent overall for breast cancer.  The strongest findings for both breast and prostate 535 
cancer were for exposure to outdoor blue-light spectrum that is probably the most 536 
biologically relevant exposure.   537 
 538 
 539 
 540 
 541 
 542 
 543 
 544 
 545 
 546 
 547 
 548 
 549 
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TABLES 711 
 712 
Table 1. Distribution of potential breast cancer risk factors among MCC-Spain 713 
participants included in the indoor-ALAN and outdoor-ALAN models (only for Madrid 714 
and Barcelona). 715 
 716 
Breast Indoor ALAN Outdoor-Visual 
Factors 
Controls  
N=1385 
N (%) 
Cases  
N=1219 
N (%) 
Controls  
n=568 
n (%) 
Cases  
n=446 
n (%) 
Age (years); mean (SD) 58.82(12.6) 55.78(11.8) 59.73(12.5) 55.11(12.2) 
Educational level 
Less than Primary school 
Primary school 
Secondary school 
University 
 
211 (15.3) 
438 (31.5) 
447 (32.2) 
289 (20.8) 
 
157 (12.9) 
410 (33.6) 
418 (34.3) 
234 (19.2) 
 
124 (21.8) 
178 (31.3) 
163 (28.7) 
103 (18.1) 
 
73 (16.4) 
145 (32.5) 
147 (33.0) 
81 (18.2) 
Urban vulnerability; mean (SD) 0.46 (0.1) 0.49 (0.1) 0.46 (0.2) 0.49 (0.1) 
BMI 
<25 
25-30 
>=30 
 
694 (50.1) 
440 (31.7) 
251 (18.0) 
 
590 (48.4) 
409 (33.5) 
220 (18.1) 
 
266 (46.8) 
187 (32.9) 
115 (20.2) 
 
203 (45.5) 
162 (36.3) 
81 (18.2) 
Smoking (ever) 
 Yes 
 No 
 
578 (41.7) 
807 (58.2) 
 
547 (44.9) 
671 (55.1) 
 
212 (37.4) 
355 (62.6) 
 
199 (44.6) 
247 (55.4) 
Family History  
 No 
 Yes 
 
1257 (90.6) 
130 (9.3) 
 
1040 (85.3) 
180 (14.8) 
 
513 (90.3) 
55 (9.7) 
 
368 (85.5) 
78 (17.5) 
Alcohol consumption; mean(SD) 5.24 (8.6) 6.19 (11.3) 5.05 (8.11) 6.32 (10.6) 
Chronotype 
Morning 
Intermediate 
Evening 
 
529(38.5) 
555(40.3) 
290(21.1) 
 
442(36.6) 
474(39.2) 
291(24.1) 
 
231 (47.7) 
186 (38.4) 
67 (13.8) 
 
165 (43.5) 
152 (40.1) 
62 (16.4) 
Menopause 
Premenopausal 
Postmenopause 
 
391(28.2) 
994(71.7) 
 
441 (36.2) 
778 (63.8) 
 
118 (20.8) 
448 (79.2) 
 
156 (35.1) 
289 (65.9) 
 717 
 718 
 719 
 720 
 721 
 722 
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Table 2. Distribution of potential prostate cancer risk factors among MCC-Spain 723 
participants included in the indoor-ALAN and outdoor-ALAN models (only for Madrid 724 
and Barcelona). 725 
 726 
Prostate Indoor ALAN Outdoor-Visual 
Factors 
Controls  
N=879 
N (%) 
Cases  
N=623 
N (%) 
Controls  
n=660 
n (%) 
Cases  
n=438 
n (%) 
Age (years); mean (SD) 66.09(8.3) 65.59(6.9) 66.02 (8.4) 65.22 (6.9) 
Educational level 
Less than Primary school 
Primary school 
Secondary school 
University 
 
125 (14.2) 
259 (29.5) 
268 (30.5) 
227 (25.8) 
 
111 (17.8) 
249 (40.0) 
146 (23.4) 
117 (18.8) 
 
109 (16.5) 
199 (30.2) 
189 (28.6) 
163 (24.7) 
 
85 (19.4) 
165 (37.7) 
101 (23.1) 
87 (19.9) 
Urban vulnerability; mean (SD) 0.49 (0.2) 0.51 (0.1) 0.46 (0.2) 0.50 (0.1) 
BMI 
<25 
25-30 
>=30 
 
234 (26.6) 
448 (50.8) 
197 (22.4) 
 
161 (25.8) 
324 (52.0) 
138 (22.2) 
 
175 (26.5) 
346 (52.4) 
139 (21.1) 
 
115 (26.3) 
224 (51.1) 
99 (22.6) 
Smoking (ever) 
 Yes 
 No 
 
644 (73.3) 
235 (26.7) 
 
467 (75.0) 
156 (25.0) 
 
499 (75.6) 
161 (24.4) 
 
324 (74.0) 
114 (26.0) 
Family History  
 No 
 Yes 
 
822 (93.5) 
57 (6.5) 
 
520 (83.5) 
103 (16.5) 
 
616 (93.3) 
44 (6.7) 
 
367 (83.8) 
71 (16.2) 
Alcohol consumption; mean(SD) 28.72 (32.0) 31.89 (35.4) 29.40  (32.8) 30.15 (33.5) 
Chronotype 
Morning 
Intermediate 
Evening 
 
430 (50.4) 
316 (37.0) 
108 (12.6) 
 
311 (50.1) 
231 (37.2) 
79 (12.7) 
 
294 (55.6) 
174 (32.9) 
61 (11.5) 
 
198 (54.9) 
120 (33.2) 
43 (11.9) 
 727 
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Table 3. Association of Indoor artificial light-at-night (ALAN) when sleeping, with 729 
breast and prostate cancer in the total MCC-Spain population (OR: odds ratio; 95% CI: 730 
95% confidence interval) 731 
 732 
 Controls/Cases 
N (%) 
ORs 
(95%CI) 
Controls/Cases 
N(%) 
ORs  
(95%CI) 
Basic adjustmenta Breast Cancer (N=2604) Prostate Cancer (N=1502) 
Indoor ALAN  
Ref= Total darkness 
Almost dark  
Dim light  
Quite illuminated 
 
196(14.1)/168(13.8) 
534(38.6)/448(36.7) 
434(31.4)/415(34.1) 
221(15.9)/188(15.4) 
 
1.0 
1.05(0.8, 1.4) 
1.30(0.9, 1.7) 
1.02(0.8, 1.4) 
 
151(17.2)/ 91(14.6) 
369(42.0)/ 218(35.0) 
266(30.3)/ 209(33.5) 
93(10.6)/ 105(17.0) 
 
1.0 
0.96(0.7, 1.3) 
1.21(0.9, 1.7) 
1.90(1.3, 2.9) 
Further adjustmentb Breast Cancer (N=1590) Prostate Cancer (N=1096) 
Indoor ALAN   
Ref= Total darkness 
Almost dark  
Dim light  
Quite illuminated 
 
126(13.5)/83(11.1) 
360(38.6)/235(37.6) 
303(32.5)/246(37.6) 
144(15.4)/93(13.6) 
 
1.0 
1.00(0.7, 1.4) 
1.27(0.9, 1.8) 
0.95(0.6, 1.4) 
 
125(18.9)/ 74(17.1) 
275(41.5)/ 135(31.1) 
207(31.3)/ 146(33.6) 
55(8.3)/ 79(18.2) 
 
1.0 
0.86(0.6, 1.3) 
1.12(0.7, 1.7) 
2.56(1.6, 4.2) 
 733 
a. Basic adjustment: age, centre, educational level and menopausal status (in breast cancer). 734 
b. Further adjustment: age, centre, educational level, urban vulnerability, body mass index 735 
(BMI), alcohol, tobacco, family history of breast/prostate cancer and chronotype. Menopausal 736 
status (only breast cancer). 737 
 738 
 739 
 740 
 741 
 742 
 743 
 744 
 745 
 746 
 747 
 748 
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Table 4. Association of indoor and outdoor artificial light-at-night (ALAN) when 749 
sleeping, with breast and prostate cancer. Subjects from Barcelona and Madrid, MCC-750 
Spain. MSI (blue light) and Visual light were divided into tertiles of exposure a,b and 751 
first tertile was the reference level (OR: odds ratio; 95% CI: 95% confidence interval). 752 
 753 
 Controls/Cases 
N (%) 
ORs  
(95%CI) 
Controls/Cases 
N(%) 
ORs  
(95%CI) 
Basic adjustmentc Breast Cancer (N=705) Prostate Cancer (N=738) 
Indoor ALAN 
Ref= Total darkness 
Almost dark  
Dim light  
Quite illuminated 
 
48(12.1)/37(12.0) 
154(38.9)/96(31.1) 
163(41.2)/152(49.2) 
31(7.8)/24(7.8) 
 
1.0 
0.85(0.5, 1.4) 
1.34(0.8, 2.3) 
1.06(0.5, 2.1) 
 
102(23.8)/64(20.6) 
155(36.2)/74(23.9) 
142(33.2)/124(40.0) 
29(6.7)/48(15.5) 
 
1.0 
0.75(0.5, 1.2) 
1.36(0.9, 2.1) 
2.88(1.6,5.1) 
ALAN-Visual Light 
 Ref=1st tertile (lowest) 
2nd tertile 
3rd tertile (highest) 
 
122(30.8)/107(34.6) 
144(36.4)/104(33.7) 
130(32.8)/98(31.7) 
 
1.0 
0.89(0.6, 1.3) 
0.91(0.6, 1.4) 
 
130(30.4)/124(40.0) 
158(36.9)/96(31.0) 
140(32.7)/90(29.0) 
 
1.0 
0.64(0.4, 1.0) 
0.64(0.43, 1.0) 
ALAN-MSI  
 Ref=1st tertile 
2nd tertile 
3rd tertile 
 
136(27.4)/106(34.3) 
236(47.6)/92(29.8) 
124(25.0)/111(35.9) 
 
1.0 
0.9(0.6, 1.3) 
1.23(0.8, 1.8) 
 
157(36.7)/98(31.6) 
151(35.3)/100(32.3) 
120(28.0)/112(36.1) 
 
1.01.18(0.8, 
1.7) 
1.79(1.2, 2.7) 
Further adjustmentd Breast Cancer (N=521) Prostate Cancer (N=659) 
Indoor ALAN   
Ref= Total darkness 
Almost dark  
Dim light  
Quite illuminated 
 
 43 (12.6)/32(12.0) 
135(39.4)/82(31.0) 
138(40.4)/128(48.3) 
26(7.6)/23(8.7) 
 
1.0 
0.79(0.4, 1.4) 
1.18(0.7, 2.1) 
1.19(0.6, 2.6) 
 
89(23.2)/61(22.2) 
145(37.8)/64(23.3) 
125(32.5)/107(38.9) 
25(6.5)/43(15.6) 
 
1.0 
0.65(0.4, 1.1) 
1.24(0.8, 2.0) 
2.82(1.5, 5.3) 
ALAN- Visual Light 
 Ref=1st tertile 
2nd tertile 
3rd tertile 
 
107(31.2)/99(37.4) 
119(34.8)/87(32.8) 
116(34.0)/79(29.8) 
 
1.0 
0.79(0.5, 1.2) 
0.72(0.4, 1.2) 
 
123(32.0)/108(39.3) 
139(36.2)/85(30.9) 
122(31.8)/82(29.8) 
 
1.0 
0.63(0.4, 1.0) 
0.60(0.4, 1.0)  
ALAN- MSI  
 Ref=1st tertile  
2nd tertile 
3rd tertile 
 
 117(34.2)/89(33.6) 
114(33.3)/80(30.2) 
111(32.5)/96(36.2) 
 
1.0 
1.11(0.7, 1.7) 
1.54(1.0, 2.4) 
 
141(36.7)/85(30.9) 
133(34.6)/92(33.5) 
110(28.7)/98(35.6) 
 
1.0 
1.33(0.8, 2.0) 
1.90(1.2, 2.9) 
 754 
a. Breast ALAN-Visual Light tertiles of exposure: 1st tertile=0.009-0.046; 2nd tertile= 0.047-755 
0.071; 3rd tertile=0.072-0.225. Prostate ALAN- Visual Light tertiles of exposure: 1st 756 
tertile=0.002-0.047; 2nd tertile= 0.048-0.073; 3rd tertile=0.074-0.225. 757 
b. Breast ALAN-MSI tertiles of exposure: 1st tertile=0.041-0.129; 2nd tertile= 0.130-0.164; 3rd 758 
tertile=0.164-0.407. Prostate ALAN-MSI tertiles of exposure: 1st tertile=0.017-0.128; 2nd 759 
tertile= 0.129-0.162; 3rd tertile=0.163-0.413 760 
c. Basic adjustment: age, centre, educational level and menopausal status (in breast cancer). 761 
d. Further adjustment: age, centre, educational level, urban vulnerability, body mass index 762 
(BMI), alcohol, tobacco, family history of breast/prostate cancer, chronotype, menopausal status 763 
(only breast cancer) and mutual adjustment for the three light exposure variables. 764 
 765 
 766 
 767 
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Table 5. Association of Outdoor ALAN-MSI (blue light) with breast and prostate 768 
cancer subphenotypes. Models with basic adjustmenta. Relative risk ratios (RRR) for 769 
Outdoor ALAN-MSI exposures in tertilesb.  770 
 771 
 772 
Outdoor- 
ALAN-MSI 
1st tertile 2nd tertile 3rd tertile 
Breast cancer N (%) RRR   N (%) RRR 95%CI N (%) RRR 95%CI 
Hormone  receptorsc 98 (31.7) 1.0 
 
100 (32.4) 0.94 (0.7, 1.4) 111 (35.9) 1.27 (0.9, 1.9) 
Erb 2+ 23 (35.9) 1.0 
 
20 (31.3) 0.69 (0.4, 1.4) 21 (32.8) 0.86 (0.4, 1.7) 
Triple negative 17 (43.6) 1.0 
 
13 (33.3) 0.78 (0.4, 1.7) 9 (23.1) 0.7 (0.3, 1.8) 
Controls 192 (33.8) - 
 
203 (35.7) - - 173 (30.5) - - 
Prostate cancer 
 
Gleason score <7 69 (32.9) 1.0 
 
65 (31.0) 1.06 (0.7, 1.6) 76 (36.2) 1.57 (1.1, 2.3) 
Gleason score >7 67(30.0) 1.0 
 
72(32.3) 1.16 (0.8, 1.7) 84 (37.7) 1.7 (1.1,  2.5) 
Controls 231(35.0) - 
 
233 (35.3) - - 196 (29.7) - - 
 773 
a. Basic adjustment: age, centre, educational level and menopausal status (in breast cancer). 774 
b. Breast ALAN-MSI tertiles of exposure: 1st tertile=0.041-0.129; 2nd tertile= 0.130-0.164; 3rd 775 
tertile=0.164-0.407. Prostate ALAN-MSI tertiles of exposure: 1st tertile=0.017-0.128; 2nd 776 
tertile= 0.129-0.162; 3rd tertile=0.163-0.413 777 
c. Hormone receptors: Estrogen or Progestagen positive receptors and Erb2 negative. 778 
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FIGURE LEGENDS 808 
Figure 1. International Space Station night image (https://eol.jsc.nasa.gov) of Madrid 809 
2012 (ISS030-E-82053). 810 
Figure 2. International Space Station night image (https://eol.jsc.nasa.gov) of Barcelona 811 
2013 (ISS045-E-120336). 812 
Figure 3. Classification of the ground level spectral type of the lampsa using the green 813 
to the red bands (G/R) ratio, to estimate the ground based spectrum of the melatonin 814 
suppression index (MSI). 815 
a. Different types of lamps used in the analysis: 816 
CFL=Compact Fluorescent 817 
MV= Mercury Vapour 818 
HAL= Halogen 819 
MH= Metallic Halogen 820 
CMH= Ceramic Metallic Halogen 821 
FL=Fluorescent 822 
LED = LED 823 
INC = Incandescent 824 
HPS = High Pressure Sodium 825 
LPS = Low Pressure Sodium 826 
 827 
 828 
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Figure 4. Relationship between the ratio of the photopic visual light over the green 829 
band fluxes detected from the ISS (V(λ)/G) to the ratio of the green to the red bands 830 
(G/R) also detected from the ISS image to classify the lamp type. 831 
Figure 5. Generalized Additive Models for breast and prostate cancer and exposure to 832 
visual light and blue light (MSI). The models were adjusted by: age, centre, educational 833 
level and menopausal status (only breast cancer). 834 
 835 
 836 
 837 
 838 
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